A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY‐PD III)

OBJECTIVE: To describe the rationale for a novel study design and baseline characteristics of a disease‐modifying trial of isradipine 10 mg daily in early Parkinson disease (PD). METHODS: STEADY‐PDIII is a 36‐month, Phase 3, parallel group, placebo‐controlled study of the efficacy of isradipine 10 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Biglan, Kevin M., Oakes, David, Lang, Anthony E., Hauser, Robert A., Hodgeman, Karen, Greco, Brittany, Lowell, Jillian, Rockhill, Rebecca, Shoulson, Ira, Venuto, Charles, Young, Diony, Simuni, Tanya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454402/
https://www.ncbi.nlm.nih.gov/pubmed/28589163
http://dx.doi.org/10.1002/acn3.412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454402/
https://www.ncbi.nlm.nih.gov/pubmed/28589163
http://dx.doi.org/10.1002/acn3.412

Ejemplares similares